When UK Prime Minister Keir Starmer welcomes business leaders to a major investment summit in London on Monday, his message ...

Cerebras is seeking to go public at a valuation of about $8 billion. There are several red flags why I won't invest in its ...

Marshall Wace LLP decreased its position in Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 80.2% during the 2nd ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

Investing.com-- China’s recent round of stimulus sparked a strong rally in local stocks over the past few weeks, but MRB ...

UK stocks saw mixed performances as dividend exclusions weighed on some major companies, while GSK shares surged post-lawsuit ...